Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies
Xlife Sciences AG
/ Key word(s): Miscellaneous
Lysatpharma, a portfolio company of Xlife Sciences (SIX: XLS), and Novaxomx, a joint-venture of Xlife Sciences and curasan (a leading global provider of biomaterials for bone and tissue regeneration in dental and orthopedic surgery), signed an exclusive license agreement. Novaxomx has obtained the exclusive rights to use Lysatpharma’s patented “exosome” technology for the research of optimizing biomimetic osteoconductive carrier materials by biologizing them with exosomes.
Novaxomx focuses on the research, development, certification, production, and marketing of disruptive, biosurgical therapies for use in musculoskeletal diseases and tissue regeneration. It’s ambition is to improve the carriers’ biofunctionality in regenerative processes such as non-union or delayed non-union fractures or bone fusion after spinal fusion procedures. Other possible applications include the treatment of chronic osteomyelitis, rheumatoid arthritis, or periodontal bone loss.
The bioactive nanovesicles are secreted from human stem cells or derived from autologous platelets. They are introduced with the carrier materials and enable intercellular communication, which is crucial for regenerative processes in the human body.
Frank Plöger, Chief Scientific Officer of Xlife Sciences AG and Managing Director of Lysatpharma GmbH, says: “Xlife Sciences and curasan founded Novaxomx in March 2022. Since then, we made already valuable progress, resulting in the licence agreement we announced today. We look forward to continuing to work on this promising R&D project, aiming at improve patients lives. Furthermore, the agreement is also another proofpoint of the continuously increasing number of research projects and achieved synergies within the broad Xlife universe.”
Dr. Dirk Dembski, CEO of curasan AG, comments: “The license Novaxomx has obtained from Lysatpharma allows Novaxomx to take an interdisciplinary approach to develop disruptive, biosurgical products that fundamentally improve bone healing. We expect that curasan's clinically proven products can then be used even more effectively for bone regeneration thanks to the targeted, innovative biologization option.”
Annual Report 2022 April 20, 2023
Ordinary AGM 2023 June 22, 2023
Half-Year Report 2023 September 21, 2023
Information for journalists: IRF Reputation AG, Valentin Handschin, firstname.lastname@example.org
Information for investors: Xlife Sciences AG, Dennis Lennartz, email@example.com
Xlife Sciences AG,
About Xlife Sciences AG (SIX: XLS)
End of Media Release
|Company:||Xlife Sciences AG|
|Phone:||+41 44 385 84 60|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1502373|
|End of News||EQS News Service|